


Amendments to the Claims

Listing of Claims

1. (Currently Amended) A method for treating and/or preventing Cardiovascular Diseasesacute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:

a) administering a compound of formula I




I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof; and

b) performing a PCI procedure percutaneous coronary intervention procedure.

2. (Currently Amended) A method for treating and/or preventing Cardiovascular Diseases acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:

a) administering a compound of formula I




I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof in combination with aspirin; and

b) performing a PCI procedurepercutaneous coronary intervention procedure.

3. (Currently Amended) A method for treating and/or preventing Cardiovascular Diseasesacute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in the order described:

a) first, administering a compound of formula I



I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin;

b) second, performing a PCI procedurepercutaneous coronary intervention procedure; and

c) third, administering a compound of formula I or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin.

4. (Currently Amended) A method according to ~~Claims 1, 2, or 3~~Claims 2 or 3 comprising in order the steps of:

a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin or other cardio protective agent about 2 to 30 days prior to performing the PCI procedure percutaneous coronary intervention procedure,


- b) performing a ~~PCI procedure~~percutaneous coronary intervention procedure, and
- c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, ~~solvate, active metabolite, prodrug, racemate or enantiomer~~ thereof, optionally in combination with aspirin ~~or other cardio protective agent~~ about 0 to 365 days after performance of the ~~PCI procedure~~percutaneous coronary intervention procedure.

5. (Currently Amended) A method according to Claim 1, 2, or 3 wherein the compound of formula I, is 2-Acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride acid addition salt ~~or enantiomer thereof~~.

6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)

10. (Currently Amended) Use of a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ~~solvate, prodrug, active metabolite, racemate or enantiomer~~ thereof, in conjunction with a stent for treating and/or preventing recurrence of ~~cerebrovascular disease~~acute coronary syndrome.

11. (Currently Amended) Use of a compound of formula I



I

or a pharmaceutically acceptable salt, ~~solvate, prodrug, racemate or enantiomer~~ thereof, in conjunction with a ~~PCI procedure~~percutaneous coronary intervention

procedure for treating and/or preventing the recurrence of ~~Cardiovascular Diseases~~ acute coronary syndrome comprising administering an effective amount of said compound of formula I optionally in combination with aspirin to a patient in need thereof.

12. (Cancelled)
13. (Cancelled)
14. (Cancelled)